The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients

George V. Papatheodoridis; Cihan Yurdaydin; George N. Dalekos; Maria Buti; Heng Chi; Florian van Boemmel; Jose L. Calleja; Vana Sypsa; Ioannis Goulis; Spilios Manolakopoulos; Alessandro Loglio; Spyros I. Siakavellas; Onur Keskin; Nikolaos Gatselis; Bettina E. Hansen; Maria Lehretz; Juan de la Revilla; Savvoula Savvidou; Anastasia Kourikou; Jiannis Vlachogiannakos; Ramazan Idilman; Kostas Galanis; Thomas Berg; Massimo Colombo; Rafael Esteban; Harry L. Janssen; Pietro Lampertico

The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients

George V. Papatheodoridis
, Cihan Yurdaydin
, George N. Dalekos
, Maria Buti
, Heng Chi
, Florian van Boemmel
, Jose L. Calleja
, Vana Sypsa
, Ioannis Goulis
, Spilios Manolakopoulos
, Alessandro Loglio
, Spyros I. Siakavellas
, Onur Keskin
, Nikolaos Gatselis
, Bettina E. Hansen
, Maria Lehretz
, Juan de la Revilla
, Savvoula Savvidou
, Anastasia Kourikou
, Jiannis Vlachogiannakos

Ramazan Idilman, Kostas Galanis, Thomas Berg, Massimo Colombo, Rafael Esteban, Harry L. Janssen, Pietro Lampertico

Division of Internal Medicine (Medicine)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	923A-923A
Number of pages	1
Journal	Hepatology
Volume	64
Publication status	Published - Oct 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Papatheodoridis, G. V., Yurdaydin, C., Dalekos, G. N., Buti, M., Chi, H., van Boemmel, F., Calleja, J. L., Sypsa, V., Goulis, I., Manolakopoulos, S., Loglio, A., Siakavellas, S. I., Keskin, O., Gatselis, N., Hansen, B. E., Lehretz, M., de la Revilla, J., Savvidou, S., Kourikou, A., ... Lampertico, P. (2016). The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients. Hepatology, 64, 923A-923A.

@article{1babf0f80a1c4556ac1ca0accc69ae79,

title = "The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients",

author = "Papatheodoridis, \{George V.\} and Cihan Yurdaydin and Dalekos, \{George N.\} and Maria Buti and Heng Chi and \{van Boemmel\}, Florian and Calleja, \{Jose L.\} and Vana Sypsa and Ioannis Goulis and Spilios Manolakopoulos and Alessandro Loglio and Siakavellas, \{Spyros I.\} and Onur Keskin and Nikolaos Gatselis and Hansen, \{Bettina E.\} and Maria Lehretz and \{de la Revilla\}, Juan and Savvoula Savvidou and Anastasia Kourikou and Jiannis Vlachogiannakos and Ramazan Idilman and Kostas Galanis and Thomas Berg and Massimo Colombo and Rafael Esteban and Janssen, \{Harry L.\} and Pietro Lampertico",

year = "2016",

month = oct,

language = "English",

volume = "64",

pages = "923A--923A",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Lippincott Williams and Wilkins",

}

Papatheodoridis, GV, Yurdaydin, C, Dalekos, GN, Buti, M, Chi, H, van Boemmel, F, Calleja, JL, Sypsa, V, Goulis, I, Manolakopoulos, S, Loglio, A, Siakavellas, SI, Keskin, O, Gatselis, N, Hansen, BE, Lehretz, M, de la Revilla, J, Savvidou, S, Kourikou, A, Vlachogiannakos, J, Idilman, R, Galanis, K, Berg, T, Colombo, M, Esteban, R, Janssen, HL & Lampertico, P 2016, 'The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients', Hepatology, vol. 64, pp. 923A-923A.

The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients. / Papatheodoridis, George V.; Yurdaydin, Cihan; Dalekos, George N. et al.
In: Hepatology, Vol. 64, 10.2016, p. 923A-923A.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients

AU - Papatheodoridis, George V.

AU - Yurdaydin, Cihan

AU - Dalekos, George N.

AU - Buti, Maria

AU - Chi, Heng

AU - van Boemmel, Florian

AU - Calleja, Jose L.

AU - Sypsa, Vana

AU - Goulis, Ioannis

AU - Manolakopoulos, Spilios

AU - Loglio, Alessandro

AU - Siakavellas, Spyros I.

AU - Keskin, Onur

AU - Gatselis, Nikolaos

AU - Hansen, Bettina E.

AU - Lehretz, Maria

AU - de la Revilla, Juan

AU - Savvidou, Savvoula

AU - Kourikou, Anastasia

AU - Vlachogiannakos, Jiannis

AU - Idilman, Ramazan

AU - Galanis, Kostas

AU - Berg, Thomas

AU - Colombo, Massimo

AU - Esteban, Rafael

AU - Janssen, Harry L.

AU - Lampertico, Pietro

PY - 2016/10

Y1 - 2016/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000385493804228&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Meeting Abstract

SN - 0270-9139

VL - 64

SP - 923A-923A

JO - Hepatology

JF - Hepatology

ER -

The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients

UN SDGs

Other files and links

Cite this